Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7595681 | 0.83 | HCAR2 (0.34) | ALDH1A1LMNATSHR | |
| SCHEMBL2610388 | 0.83 | ALDH1A1 (0.44) | ALDH1A1KMT2AMEN1PKMKDM4E | |
| SCHEMBL2110889 | 0.81 | ALDH1A1 (0.43) | ALDH1A1KMT2AMEN1PKMKDM4E | |
| SCHEMBL7591548 | 0.80 | ALDH1A1 (0.45) | ALDH1A1LMNATSHR | |
| SCHEMBL15912153 | 0.79 | ALDH1A1 (0.36) | ALDH1A1KMT2AMEN1PKMKDM4E | |
| SCHEMBL7593761 | 0.79 | NAAA (0.44) | ALDH1A1LMNATSHRNPSR1 | |
| SCHEMBL31206210 | 0.76 | KMT2A (0.33) | ALDH1A1KMT2AMEN1PKMKDM4E | |
| SCHEMBL29098193 | 0.75 | ALDH1A1 (0.36) | ALDH1A1KMT2AMEN1PKMKDM4E | |
| SCHEMBL95855 | 0.75 | DGAT1 (0.34) | ALDH1A1GAA | |
| SCHEMBL1979744 | 0.74 | ALDH1A1 (0.48) | ALDH1A1KMT2AMEN1PKMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112679328-A | Industrial production method of 3-trifluoromethyl-2-cyclohexene-1-ketone | 南京药石科技股份有限公司 | 2021-04-20 | — | — | CN | claimed |
| WO-2026098683-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | 盛睿泽华医药科技（苏州）有限公司 | 2026-05-15 | — | — | WO | disclosed |
| WO-2026087650-A1 | VINYLOXY-ARYL COMPOUNDS FOR THE TREATMENT OF CANCER | SANOFI (FR) | 2026-04-30 | — | — | WO | disclosed |
| US-20260042760-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | ACONCAGUA BIO INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12486269-B2 | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity | ACONCAGUA BIO, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250257067-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | ACONCAGUA BIO, INC. | 2025-08-14 | — | — | US | disclosed |
| US-20250059161-A1 | COMPOUNDS AND METHODS FOR MODULATING STAT3 | VIVIDION THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| WO-2025031396-A1 | SUBSTITUTED BENZOCYCLOBUTENE COMPOUND AND USES THEREOF IN THE FIELD OF MEDICINE | 杭州安道药业有限公司 | 2025-02-13 | — | — | WO | disclosed |
| EP-4479045-A2 | INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2024182693-A1 | 2-AZASPIRO[3.3]HEPTANE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER | VIVIDION THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20100204218-A1 | FUSED BICYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-08-12 | — | — | US | disclosed |
| US-20100203446-A1 | CHEMICALLY AMPLIFIED PHOTORESIST COMPOSITION AND METHOD FOR FORMING PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-08-12 | — | — | US | disclosed |
| EP-2179994-A1 | FUSED BICYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-28 | — | — | EP | disclosed |
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1984345-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007089034-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| EP-0968994-B1 | PROCESS FOR PRODUCING SUBSTITUTED TRIFLUOROBENZOIC ACIDS AND ESTERS THEREOF | UBE INDUSTRIES (JP) | 2002-11-06 | — | — | EP | disclosed |
| US-6307091-B1 | TRIFLUOROMETHYLATING A TRIFLUOROIODOBENZOIC ACID ESTER WITH ADIFLUORO(FLUOROSULFONYL)ACETIC ACID ESTER IN THE PRESENCE OF A COPPER CATALYST IN AN ORGANIC SOLVENT. | UBE INDUSTRIES, LTD. (JP) | 2001-10-23 | — | — | US | disclosed |
| US-6160171-A | Trifluoro-substituted benzoic acid, esters thereof, and process for producing the same | UBE INDUSTRIES, LTD. (JP) | 2000-12-12 | — | — | US | disclosed |
| EP-0968994-A1 | SUBSTITUTED TRIFLUOROBENZOIC ACIDS, ESTERS THEREOF, AND PROCESS FOR PRODUCING THE SAME | UBE INDUSTRIES, LTD. (JP) | 2000-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486269-B2 | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity | IAPP, GIPR, SCTR | ALDH1A1 4002/4885KMT2A 4800/4885MEN1 812/4885 |
| US-20100204218-A1 | FUSED BICYCLIC COMPOUND | NR3C2, NR3C1, MC2R | ALDH1A1 4064/4885KMT2A 1288/4885MEN1 1147/4885 |
| US-20260042760-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | NPY1R, CALCRL, SCTR | ALDH1A1 3320/4885KMT2A 4755/4885MEN1 750/4885 |
| US-20250257067-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | IAPP, GIPR, SCTR | ALDH1A1 4002/4885KMT2A 4800/4885MEN1 812/4885 |
| US-20250059161-A1 | COMPOUNDS AND METHODS FOR MODULATING STAT3 | STAT3, JAK2, STAT1 | ALDH1A1 2652/4885KMT2A 1076/4885MEN1 4461/4885 |
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | NR3C2, MC2R, NR3C1 | ALDH1A1 2133/4885KMT2A 2504/4885MEN1 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.